Mode
Text Size
Log in / Sign up
N/A N=75 Other

Testing of a Valsalva Assist Device (VAD) in Healthy Volunteers Performing a Valsalva Manoeuvre

SVT · Vagal Bradycardia

Enrolled (actual)
75
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcome: Primary: Assessing Heart Rate During the Supine and Modified VM and Assessing Heart Rate While Using the VAD and Manometer — 33.6; 25.9; 28.7; 30.8 beat per minute — p=<0.001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Supine VM VAD (Device); Supine VAD manometer (Device); Modified VM VAD (Other); Modified VM Manonmeter (Other)
Age
Adult · 18+ yrs
Sex
All
Sponsor
University of Exeter
Primary completion
Feb 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Assessing Heart Rate During the Supine and Modified VM and Assessing Heart Rate While Using the VAD and Manometer
33.6; 25.9; 28.7; 30.8 <0.001 sig
SECONDARY
Percentage of Participants Who Acheived a 15 Second Strain Duration During a VM Comparing a Valsalva Assist Device and a Standard Manometer
56; 73
SECONDARY
Peak Sustained Pressure Testing of a Valsalva Assist Device (VAD) Compared to the Standard Manometer
42.46; 39.96

Summary

A prototype for a Valsalva Assist Device (VAD), which provides resistance to exhalation, has been developed and is ready for testing in healthy volunteers. There is a need to ensure the device can deliver the required strain and evaluate the physiological response (lowered heart rate) when used to deliver a Valsalva manoeuvre (VM) with and without postural modification.

Eligibility Criteria

Inclusion Criteria

  • Adult Volunteers between 18 and 60 years old from University of Exeter or RD&E Hospital staff
  • Sinus rhythm on initial ECG
  • Self-reported good health

Exclusion Criteria

  • Any regular medication other than the oral contraceptive
  • Previous cardiovascular or respiratory disease
  • Any contraindication to performing a VM strain. (Eg. Known aortic stenosis, recent myocardial infarction, glaucoma, retinopathy)
  • Pregnancy
  • Any ECG abnormality
  • Any contra-indication to postural modification (any reason the participant can't lie flat and have both legs lifted to 45 degrees, eg prosthetic hip
  • Inability or refusal to give written consent to take part
  • Observations of heart rate, oxygen saturations, respiratory rate or blood pressure outside the normal range. Specifically blood pressure less than 100 systolic
  • Caffeinated drinks within 6 hours prior to testing
  • The use of stimulant drugs or alcohol within 24 hours prior to testing
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03298880). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search